ITRMF — Iterum Therapeutics plc
$0.00
+$0.00 (+0.00%)
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options.
Market Cap
$532.00
Forward P/E
N/A
52-Week Range
N/A
ITRMF Price History
Revenue vs. Net Income
$0
Revenue · FY2024
Annual. Net margin is shown under each year.
Free Cash Flow
-$26.8M
FCF · FY2024
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-81.6%
ROCE · FY2024
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.9x
Assets ÷ liabilities · FY2024
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+40.1%
Dilution · FY2024
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
